持续亏损，多股东套现 纳芯微赴港IPO

Group 1 - The core viewpoint of the news is that Silver诺医药 is set to launch its IPO on the Hong Kong Stock Exchange, focusing on its weight loss drug and raising approximately HKD 610 million for clinical trials and commercialization [1][2] - The company plans to issue 36.56 million shares at a price of HKD 18.68 per share, with 10% allocated for public offering in Hong Kong and the remainder for international investors [1] - The company has secured cornerstone investors, including Junsheng and Ginkgo Fund, with a total subscription amount of USD 10 million (approximately HKD 78.5 million) [1] Group 2 - Silver诺医药, founded in 2014, specializes in innovative therapies for diabetes and metabolic diseases, with its lead product,依苏帕格鲁肽α, approved for treating type 2 diabetes [2] - The company has not recorded any revenue for the years 2023 and 2024, with R&D expenses of approximately HKD 492 million and HKD 103 million, and losses of HKD 733 million and HKD 175 million respectively [2] - As of May 31, 2025, the company generated revenue of HKD 38.14 million from sales of 依苏帕格鲁肽α in China [2]